8 results about "Multinucleate giant cell" patented technology

A kind of H&E image ovarian cancer polyploid giant cell (PGCCs) detection method based on deep learning, including constructing specific data set, image annotation and data division, using OCDet model to carry out feature learning and optimization, and model training and evaluation.The method first establishes the H&E staining image data set containing PGCCs, then accurately labels the image and divides it into training, verification and test set.OCDet model takes CSPDarkNet as the core, combines ECA mechanism, focuses on the deep learning and re-encoding of pathological semantic features.Through the training data set, the model updates parameters through back propagation and gradient descent, optimizes to identify PGCCs features.The verification set is used for model tuning, and the test set is used for evaluating the performance of the model.The automatic detection technology of the application can help doctors improve the diagnosis efficiency and reduce the error, provide an important reference for clinical treatment and prognosis evaluation, and show significant clinical application value.

The invention relates to the technical field of biological medicine, and discloses a targeting molecule for inhibiting generation of PD-L1 and giant cells mediated by a tumor exosome HMGB1 and application of the targeting molecule, the targeting molecule comprises a first binding unit, a second binding unit and a flexible connecting peptide for connecting the first binding unit and the second binding unit; the amino acid sequence of the first binding unit is Asp-Gly-Arg-Tyr-Phe-Leu-Ser-Pro-Asn-Lys, and the first binding unit can be specifically bound with a binding boundary of a C-terminal acid tail of HMGB1 on the surface of a tumor exosome and RAGE; the amino acid sequence of the second binding unit is Trp-His-Glu-Val-Met-Ala-Gln-Ile-Arg-Ser, and the second binding unit can be specifically bound with an extracellular structural domain of PD-L1 on the surface of the macrophage; the amino acid sequence of the flexible connecting peptide is Gly-Gly-Ser-Gly, and the amino acid sequence of the flexible connecting peptide is Gly-Gly-Ser-Gly. In order to achieve the purpose of specifically inhibiting PD-L1 expression mediated by tumor exosome HMGB1 and giant cell generation, a targeting molecule containing a bispecific binding unit is designed, a first binding unit is specifically bound with a specific binding interface of the tumor exosome surface HMGB1, and a second binding unit is specifically bound with an extracellular structural domain of PD-L1 on the macrophage surface; therefore, the purpose is achieved.

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject.

Disclosed is the characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterization in the screening, diagnosis, treatment, and recurrence of cancer. [Selection diagram] Figure 4

The characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterizations in cancer screening, diagnostics, treatment, and recurrence, are disclosed.

The present invention provides a method for producing a nephron precursor cell conditioned medium, the method comprising the following steps: (1) a step for subjecting 500 or more cell masses of nephron precursor cells having a diameter of 150-600 μm to suspension culture in the same culture vessel to form a giant cell mass in which the cell masses are fused; and (2) a step for culturing the giant cell mass obtained in the step (1) in a medium in which nephron precursor cells are maintained and amplified to obtain a conditioned medium. The present invention also provides a conditioned medium obtained by said method, and a renal protection factor or the like secreted specifically in the conditioned medium.